Aberdeen Group
LENZ

Aberdeen Group’s LENZ Therapeutics LENZ Stock Holding History

Aberdeen Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.79M Buy
1,547,883
+391,722
+34% +$3.16M 0.01% 623
2026
Q1 		$10.6M Buy
1,156,161
+666,729
+136% +$9.37M 0.02% 582
2025
Q4 		$7.83M Buy
489,432
+358,706
+274% +$10.5M 0.01% 648
2025
Q3 		$6.09M Buy
130,726
+56,440
+76% +$2.08M 0.01% 680
2025
Q2 		$2.18M Buy
+74,286
New +$2.02M ﹤0.01% 775

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Aberdeen Group's LENZ Position: Q2 2026 in Review

Aberdeen Group increased its LENZ Therapeutics (LENZ) stake by 34% in Q2 2026, buying an estimated $3.16M and bringing the position to 1,547,883 shares worth $8.79M. The position accounts for 0.01% of the portfolio, ranked #623.

Aberdeen Group first reported a position in LENZ in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.6M in Q1 2026. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Aberdeen Group held 1,547,883 shares of LENZ Therapeutics worth $8.79M as of Q2 2026.
  • Aberdeen Group bought 391,722 LENZ Therapeutics shares in Q2 2026, an estimated $3.16M.
  • LENZ Therapeutics made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #623 holding.
  • Aberdeen Group first reported a position in LENZ Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Aberdeen Group's LENZ Therapeutics position peaked at $10.6M in Q1 2026.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.